Primary screening based on detection of human papillomavirus (HPV) has proved to be more sensitive than cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN). Self-sampling for specimen collection may also improve the participation rate, especially in the non-responder group. However, HPV is highly prevalent and therefore HPV detection has a lower specificity in cervical cancer screening than cytology. In addition to the clinically validated HPV test, HPV dynamics should be taken into account. It is important to identify women with a chronic productive infection likely to cause, or to already have caused, high-grade CIN or cervical carcinoma, and to limit overtreatment of women with a transient infection. Furthermore, the introduction of the HPV vaccine is likely to lower the incidence of CIN and cervical carcinoma, which will lower the positive predictive value of cervical cancer screening. This potential impact needs to be taken into account when planning for future screening guidelines.
The introduction of human papillomavirus (HPV) testing into cervical screening programmes seems to be inevitable. However, HPV is a highly prevalent virus that is mainly transient. Therefore, it is important to understand HPV dynamics and to identify women at high risk of cervical intraepithelial neoplasia (CIN) or cervical carcinoma to avoid overtreatment. Persistent HPV infection is necessary for the development of high-grade CIN or cervical carcinoma. • When an HPV type is detected, when does a woman have a productive (replicating) infection?
• When is the detected HPV type infectious? (i.e., when is there a high risk of transmission to a sexual partner?)
• When is a newly detected HPV type truly a new infection and when does it represent a re-infection or reactivation?
To answer these questions, we must consider the role of the immune system and the role of the viral load.
Productive Human Papillomavirus Infection
The presence of HPV may indicate a productive (replicating) infection or not. It is important to realise that an infection is more than the detection of the pathogen. Infection is invasion by, and multiplication of, pathogenic microorganisms in bodily tissue, which may produce tissue injury and progress to disease through a variety of cellular or toxic mechanisms.
When studying the HPV life-cycle, initial infection requires access of infectious particles to cells in the basal layer through microabrasions. 
Transmission of Human Papillomavirus
The immune system is important in the natural control of the spread of HPV-associated disease. The immune system may clear the infection or control the virus by keeping it at a low copy number.
Transmission dynamics are dependent on both pathogen and host factors and are defined by three components:
• transmissibility from an infected to an uninfected partner upon exposure;
• the likelihood of exposure between infected and uninfected persons; and
• the time for which a person is infectious. Human Papillomavirus -When Is It Newly Acquired, a Re-infection or a Reactivation?
Short-term fluctuations of HPV in an individual suggest that some detected HPV types might be newly acquired whereas others might have been acquired in the past and remained latent, below detection level for a certain period, and then been reactivated.
Reactivation of latent HPV infections was observed in HIV-infected
women; however, few reactivation events were identified in HIV-uninfected women. 24 The most important factor consistently associated with reactivation in HIV-infected women is a CD4 count less than 200 mm 3 . 24 This variety in data on HPV seroprevalence demonstrates that the host immune response against HPV is only partially understood and that HPV serology is a poor marker of current infections or related lesions.
Human Papillomavirus DNA Detection in Cervical Cancer Screening
To date, HPV DNA testing has been used in most cervical screening programmes as a triage test for women who have abnormal cytology.
However, HPV DNA-based primary screening has proved to be more sensitive than cytology in detecting high-grade CIN, but with a lower specificity. 27, 28 Additionally, HPV DNA-based primary screening may also improve the participation rate, especially when self-sampling is used for specimen collection, thereby increasing the overall effectiveness of the screening programme. 29, 30 Self-sampling has been proved to have a sufficient sensitivity to screen women otherwise not screened, but further research is necessary before wide implementation in a national screening programme is possible.
To improve the specificity of HPV DNA-based primary screening, HPV dynamics should be taken into account. 2 HPV dynamics can indicate whether a detected high-risk HPV type can be considered as:
• a newly acquired infection, or re-infection, or reactivation, that could be a transient infection or potentially persisting and causing CIN within several years;
• an already persistent infection likely to cause/have caused a CIN or cervical carcinoma (i.e., a chronic productive infection); or
• an accidental pick-up of a latent infection.
HPV persistence as a clinical marker may be of value to identify women who are at high risk of cervical cancer. Repeat (genotype-specific) HPV DNA testing at 12 months may therefore be a valuable tool to identify women at increased risk of CIN and cervical cancer. 31 HPV genotyping might be used as an additional tool to decide whether to treat or not, Novel biomarkers -immunologic, genetic or viral factors -may be useful for triage in HPV DNA detection-based primary screening to support decision-making on treatment or a 'wait and see' policy. 35, 36 Currently developed biomarkers are E6 and E7 HPV messenger RNA transcripts, methylation of several genes, markers for viral integration and of chromosomal instability, and markers of increased cell proliferation such as Ki-67 and p16. 
Dynamics of Human
Papillomavirus and Cervical Cancer Screening because some types are more likely to persist than others. 31 Especially for women under
Influence of Human Papillomavirus (HPV) Vaccination on HPV Dynamics
As an increasing proportion of the population is vaccinated, the prevalence of cervical abnormalities will decrease. However, given the lag in time between HPV infection and the development of cervical cancer, (universal) vaccination is likely to have only a minimal impact on CIN and cervical cancer rates until 10-20 years from now. 43 Additionally, vaccination against HPV cannot provide 100 % protection against cervical carcinoma and its precursor lesions and little is known about the potential long-term benefit of (cross-)type immune response. Therefore, vaccinated women still need to be followed and cervical cancer screening programmes must continue.
The potential impact of HPV vaccination on the epidemiology of HPV and the rate of abnormal cytology depends on the following variables:
• vaccination coverage;
• the duration of vaccine-induced immune protection;
• the target high-risk HPV types of the vaccine;
• the rate of cross-protection; and
• whether HPV type replacement takes place.
In 2009, the UK and Australia used school-based vaccination programmes and achieved a high three-dose completion rate of approximately 80 and 70 %, respectively. 44, 45 In the Netherlands, however, only 52 % of the girls in the target age group received the HPV vaccine. When vaccination coverage is less than 90 %, herd immunity obtained by only vaccinating women may be insufficient to eradicate the targeted HPV types. 46 When considering vaccinating boys to increase herd immunity, the potential gain of a further reduction of cervical cancer must also be carefully weighed against the extra costs. It appears that, when female programmes obtain high (over 75 %) coverage, the vaccination of males provides only a small additional benefit and is not cost-effective. 47 In species. 53 Although these results are encouraging, the duration of cross-protection is unknown.
Currently, the efficacy of a broad-spectrum vaccine (Merck) against nine HPV types, including seven oncogenic HPV types, is being studied in a randomised phase III trial. When a polyvalent vaccine against nine HPV types is implemented, the prevalence of the majority of cervical cancer-associated HPV types will be drastically decreased and the discussion on cross-protection will change.
There is a possibility that the distribution of HPV types may gradually change in vaccinated populations to fill the vacated ecologic niches after the elimination of HPV types 16 and 18. 54, 55 Type replacement is a viral population dynamics phenomenon and is defined as elimination of some types causing an increase in incidence of other types. This effect can occur only if two conditions apply:
• there exists partial competition among different types during natural infection; and
• the vaccine does not afford cross-protection against types affected by this natural competition. 55 Future epidemiologic studies are needed to show whether type replacement occurs.
Challenges to Primary Cervical Cancer Screening After Vaccination
The potential impact of HPV vaccination needs to be taken into account when planning for future screening guidelines. It is estimated that there will be a 50-60 % reduction in colposcopy referrals owing to prevention of HPV 16 and 18 lesions. This will lower the positive predictive value of any screening test for cervical cancer. 56 However, HPV testing is automated and therefore more objective, and thus is less likely to be influenced by this effect than cytology. 57 Owing to the high costs of vaccination, it is important to restrict the costs of cervical screening programmes and implement an approach based on vaccine implementation. 58 However, later and less frequent screening will probably become an acceptable worldwide policy only if vaccination uptake is high across all social and economic strata. 59 To help develop new guidelines for cervical cancer screening algorithms in the post-vaccine era, future epidemiologic studies should monitor HPV prevalence, type replacement, the level of protection against HPV 16
and 18, the level of cross-protection, the duration of protection and the population coverage of the vaccination. 
